---
title: "Kleijnen Systematic Reviews (United Kingdom)"
description: "From 2017 to 2026 (so far), authors at Kleijnen Systematic Reviews (United Kingdom) took part in 40 papers in the tracked journals, most of them in health economics and policy (38) and statistics (2). 3 of them were published in 2025, against 6 in 2017."
url: https://scholar4ai.com/companies/kleijnen-systematic-reviews-united-kingdom
markdown_url: https://scholar4ai.com/companies/kleijnen-systematic-reviews-united-kingdom.md
license: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
share_text: "From 2017 to 2026 (so far), authors at Kleijnen Systematic Reviews (United Kingdom) took part in 40 papers in the tracked journals, most of them in health economics and policy (38) and statistics (2). 3 of them were… (as of 2026-11-05)"
data_url: https://scholar4ai.com/data/rankings.json
updated: 2026-11-05T06:02:37+09:00
window: 2026-10-07 to 2026-11-05
source: OpenAlex (CC0)
---

# Kleijnen Systematic Reviews (United Kingdom)

[Browse company research profiles](https://scholar4ai.com/companies/directory/page/2.md)

Papers in the tracked journals with an author at Kleijnen Systematic Reviews (United Kingdom): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education.

Back to the ranking: https://scholar4ai.com/rankings/companies.md

## Key findings

- From 2017 to 2026 (so far), authors at Kleijnen Systematic Reviews (United Kingdom) took part in 40 papers in the tracked journals, most of them in health economics and policy (38) and statistics (2).
- 3 of them were published in 2025, against 6 in 2017.
- Since 2023, the institutions with the most of these papers were Maastricht University Medical Centre (8), Care and Public Health Research Institute (4) and Erasmus University Rotterdam (4).
- The journals publishing most of them were PharmacoEconomics (14).
- The most-cited of them is “Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal” (PharmacoEconomics, 2017), with 32 citations.
- Since 2023, papers in the tracked journals cited 13 of its papers 19 times; 89% of those links came from papers with a university author and 16% from its own papers.
- Its own papers since 2023 cite archived papers 14 times, 36% of them papers with a company author.
- Across everything OpenAlex indexes, Kleijnen Systematic Reviews (United Kingdom) has 360 works with 265,391 citations (h-index 124).
- The tracked journals hold 36 of its 166 works in OpenAlex from 2017 to 2025 (21.7%).
- Its main research topics in OpenAlex are Meta-analysis and systematic reviews (73), Health Systems, Economic Evaluations, Quality of Life (72) and Clinical practice guidelines implementation (35).

## Papers per year

*Papers per publication year and category*

| Category | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (so far) |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| [Health Economics and Policy](https://scholar4ai.com/categories/health-economics-and-policy.md) | 4 | 7 | 4 | 4 | 2 | 3 | 5 | 2 | 3 | 4 |
| [Statistics](https://scholar4ai.com/categories/statistics.md) | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| All categories | 6 | 7 | 4 | 4 | 2 | 3 | 5 | 2 | 3 | 4 |

## Where the papers come from

*Journals with the most papers, since 2023*

| # | Journal | Papers |
|---:|---|---:|
| 1 | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 14 |

*Institutions with the most papers, since 2023*

| # | Institution | Papers |
|---:|---|---:|
| 1 | Maastricht University Medical Centre | 8 |
| 2 | Care and Public Health Research Institute | 4 |
| 3 | [Erasmus University Rotterdam](https://scholar4ai.com/institutions/erasmus-university-rotterdam.md) | 4 |
| 4 | [Maastricht University](https://scholar4ai.com/institutions/maastricht-university.md) | 4 |
| 5 | Radboud University Medical Center | 4 |
| 6 | Radboud University Nijmegen | 3 |
| 7 | University Medical Center Groningen | 2 |
| 8 | [University of Groningen](https://scholar4ai.com/institutions/university-of-groningen.md) | 2 |
| 9 | Isala | 1 |

*Countries with the most papers, since 2023*

| # | Country | Papers |
|---:|---|---:|
| 1 | United Kingdom | 14 |
| 2 | Netherlands | 13 |
| 3 | Canada | 1 |

*Keywords with the most papers, since 2023*

| # | Keyword | Papers |
|---:|---|---:|
| 1 | [cost-effectiveness](https://scholar4ai.com/keywords/cost-effectiveness.md) | 10 |
| 2 | NICE single technology appraisal | 6 |
| 3 | NICE guidelines | 4 |
| 4 | NICE technology appraisal | 3 |
| 5 | [health technology assessment](https://scholar4ai.com/keywords/health-technology-assessment.md) | 3 |
| 6 | [health-related quality of life](https://scholar4ai.com/keywords/health-related-quality-of-life.md) | 3 |
| 7 | incremental cost-effectiveness ratio | 3 |
| 8 | cost comparison | 2 |
| 9 | economic modeling | 2 |
| 10 | indirect treatment comparison | 2 |

## Most-cited papers

*Most-cited papers since 2017*

| # | Citations | Per month | Title | Journal | Published | Authors |
|---:|---:|---:|---|---|---|---|
| 1 | 32 | 0.3 | [Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal](https://doi.org/10.1007/s40273-017-0528-y) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2017-06-27 | Nasuh Büyükkaramikli, Hedwig M. Blommestein, Rob Riemsma et al. |
| 2 | 26 | 0.3 | [A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective](https://doi.org/10.1007/s40273-019-00795-4) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2019-04-04 | Steve Ryder, Kathleen M. Fox, Pratik P. Rane et al. |
| 3 | 19 | 0.2 | [Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal](https://doi.org/10.1007/s40273-019-00851-z) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2019-11-08 | Xavier Pouwels, Svenja Petersohn, Vanesa Huertas Carrera et al. |
| 4 | 18 | 0.2 | [Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal](https://doi.org/10.1007/s40273-018-0738-y) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2018-11-13 | Bram L. T. Ramaekers, Rob Riemsma, Sabine Elisabeth Grimm et al. |
| 5 | 16 | 0.2 | [EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties](https://doi.org/10.1007/s40258-018-0393-7) | [Applied Health Economics and Health Policy](https://scholar4ai.com/journals/applied-health-economics-and-health-policy.md) | 2018-05-28 | Rumona Dickson, Angela Boland, Rui V. Duarte et al. |
| 6 | 14 | 0.2 | [Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox–Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal](https://doi.org/10.1007/s40273-020-00932-4) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2020-06-09 | Ben F. M. Wijnen, Nigel Armstrong, Bram L. T. Ramaekers et al. |
| 7 | 13 | 0.1 | [Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal](https://doi.org/10.1007/s40273-018-0708-4) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2018-09-07 | Nasuh Büyükkaramikli, Saskia de Groot, Rob Riemsma et al. |
| 8 | 13 | 0.1 | [Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal](https://doi.org/10.1007/s40273-018-0723-5) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2018-10-06 | Sabine Elisabeth Grimm, Nigel Armstrong, Bram L. T. Ramaekers et al. |
| 9 | 11 | 0.1 | [Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal](https://doi.org/10.1007/s40273-017-0581-6) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2017-10-31 | Nasuh Büyükkaramikli, Saskia de Groot, Debra Fayter et al. |
| 10 | 11 | 0.1 | [Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal](https://doi.org/10.1007/s40273-018-0629-2) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2018-02-26 | Bram L. T. Ramaekers, Robert F. Wolff, Xavier Pouwels et al. |

## Who cites its research

*Institutions whose papers cite it most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | Maastricht University Medical Centre | Funder | Netherlands | 2 |
| 2 | [University of Sheffield](https://scholar4ai.com/institutions/university-of-sheffield.md) | University | United Kingdom | 2 |
| 3 | Universidad Complutense de Madrid | University | Spain | 1 |
| 4 | [Harvard University](https://scholar4ai.com/institutions/harvard-university.md) | University | United States | 1 |
| 5 | Radboud University Nijmegen | University | Netherlands | 1 |
| 6 | China Pharmaceutical University | University | China | 1 |
| 7 | Carol Davila University of Medicine and Pharmacy | University | Romania | 1 |
| 8 | [The University of Melbourne](https://scholar4ai.com/institutions/the-university-of-melbourne.md) | University | Australia | 1 |
| 9 | [Universidad de Granada](https://scholar4ai.com/institutions/universidad-de-granada.md) | University | Spain | 1 |

## What its papers cite

*Institutions its papers cite most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | Maastricht University Medical Centre | Funder | Netherlands | 3 |
| 2 | [Maastricht University](https://scholar4ai.com/institutions/maastricht-university.md) | University | Netherlands | 3 |
| 3 | Care and Public Health Research Institute | Research facility | Netherlands | 3 |
| 4 | [University of Liverpool](https://scholar4ai.com/institutions/university-of-liverpool.md) | University | United Kingdom | 2 |
| 5 | National Institute for Health and Care Excellence | Government | United Kingdom | 2 |
| 6 | Luxembourg Institute of Health | Nonprofit | Luxembourg | 2 |
| 7 | Zorginstituut Nederland | Funder | Netherlands | 2 |
| 8 | Novartis (United Kingdom) | Company | United Kingdom | 2 |
| 9 | [University of York](https://scholar4ai.com/institutions/university-of-york.md) | University | United Kingdom | 2 |

More: https://scholar4ai.com/corporate-citations.md · https://scholar4ai.com/industry-university.md

## In OpenAlex

*Kleijnen Systematic Reviews (United Kingdom) in OpenAlex*

| Item | Value |
|---|---|
| Type | Company |
| Location | York, England, United Kingdom |
| Also known as | KSR |
| Works in OpenAlex | 360 |
| Citations | 265,391 |
| h-index | 124 |
| i10-index | 570 |
| 2-year mean citedness | 3.08 |
| Website | [www.systematic-reviews.com](https://www.systematic-reviews.com) |
| ROR | [ror.org/004g82f36](https://ror.org/004g82f36) |
| OpenAlex | [openalex.org/I4210088647](https://openalex.org/I4210088647) |

*Works and citations per year in OpenAlex, and its papers in the tracked journals*

| Year | Works in OpenAlex | Citations received | In the tracked journals | Share |
|---|---:|---:|---:|---:|
| 2026 (so far) | 17 | 7,133 | 4 | 23.5% |
| 2025 | 11 | 9,073 | 3 | 27.3% |
| 2024 | 18 | 10,096 | 2 | 11.1% |
| 2023 | 15 | 10,322 | 5 | 33.3% |
| 2022 | 17 | 11,656 | 3 | 17.6% |
| 2021 | 11 | 15,451 | 2 | 18.2% |
| 2020 | 31 | 12,842 | 4 | 12.9% |
| 2019 | 21 | 8,742 | 4 | 19.0% |
| 2018 | 19 | 6,832 | 7 | 36.8% |
| 2017 | 23 | 5,936 | 6 | 26.1% |

*Main research topics (OpenAlex, all works)*

| # | Topic | Field | Works |
|---:|---|---|---:|
| 1 | Meta-analysis and systematic reviews | Decision Sciences | 73 |
| 2 | Health Systems, Economic Evaluations, Quality of Life | Economics, Econometrics and Finance | 72 |
| 3 | Clinical practice guidelines implementation | Medicine | 35 |
| 4 | Delphi Technique in Research | Social Sciences | 32 |
| 5 | Colorectal Cancer Treatments and Studies | Medicine | 24 |

From OpenAlex's own record of the institution (CC0), read again monthly. Works and citations count everything OpenAlex indexes, not only the tracked journals; topics are OpenAlex's classification of those works.

## Cite this page

Scholar4AI. (2026). Kleijnen Systematic Reviews (United Kingdom). Journal and Conference Research Rankings. Retrieved November 5, 2026, from https://scholar4ai.com/companies/kleijnen-systematic-reviews-united-kingdom

```bibtex
@misc{scholar4ai-companies-kleijnen-systematic-reviews-united-kingdom,
  author = {{Scholar4AI}},
  title = {Kleijnen Systematic Reviews (United Kingdom)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/kleijnen-systematic-reviews-united-kingdom}},
  urldate = {2026-11-05},
  note = {Journal and Conference Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}
```

License: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/).